AVT001

AVT001 is an autologous dendritic cell therapy developed by Avotres for the treatment of type 1 diabetes mellitus and other autoimmune diseases. The therapy consists of autologous (patient-derived) dendritic cells designed to modulate immune responses by targeting Qa-1/HLA-E restricted CD8+ regulatory T cells, which play a role in maintaining self-tolerance and preventing autoimmune destruction. In clinical studies, AVT001 has demonstrated a favorable safety profile with no dose-limiting adverse events and potential signals of efficacy in preserving C-peptide levels in patients with recent-onset type 1 diabetes. The drug is administered intravenously and is being investigated for multiple indications beyond type 1 diabetes, including lupus, multiple sclerosis (relapsing-remitting and progressive), transplantation rejection prevention, pemphigus, dermatomyositis, psoriasis, psoriatic arthritis, rheumatoid arthritis, cutaneous lupus erythematosus, chronic graft rejection and vitiligo[3][4][5].